All In Biotech

Drug Trial Radar · NCT05041309

Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

1,500

Planned (sponsor's estimate)

Start

Dec 15, 2021

Primary completion

Dec 2040

Study completion Dec 2040

Sponsor

Lead sponsor
Kite, A Gilead CompanyGilead Sciences (GILD)
Sponsor type
Industry
First posted
Sep 13, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, anitocabtagene autoleucel, INT2104, KITE-512, ACLX-001, and ACLX002 in participants of Kite-sponsored interventional studies. The primary objectives of this study are to: * Evaluate the incidence and severity of related SAEs, late-onset targeted AEs/SAEs suspected to be possibly related to gene-modified cell therapy, including neurologic disorders, new autoimmune disorders (which are distinct from the study-treated disease), hematologic disorders, serious infections, as well as any new malignancies (regardless of causality) * Evaluate the growth, development, and sexual maturity of pediatric and adolescent participants treated with gene-modified cell therapy.

Conditions

  • Solid and Hematological Malignancies
  • Autoimmune Diseases

Interventions

  • Axicabtagene CiloleucelBiological

    No investigational product will be administered

  • Brexucabtagene AutoleucelBiological

    No investigational product will be administered

  • Anitocabtagene autleucelBiological

    No investigational product will be administered

  • KITE-753Biological

    No investigational product will be administered

  • KITE-197Biological

    No investigational product will be administered

  • KITE-363Biological

    No investigational product will be administered

  • INT2104Biological

    No investigational product will be administered

  • KITE-512Biological

    No investigational product will be administered

  • SPRX001Biological

    No investigational product will be administered

  • SPRX002Biological

    No investigational product will be administered

  • ARC-T CellsBiological

    No investigational product will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing Late-onset Targeted Adverse Events (AEs)Time frame: Up to 15 years
  2. Percentage of Participants Experiencing Late-onset Targeted Serious Adverse Events (SAEs)Time frame: Up to 15 years
  3. Percentage of Participants With New MalignanciesTime frame: Up to 15 years
  4. Percentage of Participants Experiencing Related SAEsTime frame: Up to 15 years
  5. Height of Pediatric and Adolescent ParticipantsTime frame: Up to 15 years
  6. Weight of Pediatric and Adolescent ParticipantsTime frame: Up to 15 years
  7. Sexual Maturation of Pediatric and Adolescent Participants Assessed by Tanner Pubertal Stage Scale ScoreTime frame: Up to 15 years

Locations

91 sites in 14 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • City of Hope

    Duarte, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Children's Hospital Los Angeles

    Los Angeles, California

  • University of California Los Angeles

    Los Angeles, California

  • Children's Hospital of Orange County

    Orange, California

  • Stanford University

    Palo Alto, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • University of California, San Francisco Medical Center

    San Francisco, California

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Sylvester Comprehensive Cancer Centre

    Miami, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Ann& Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of Chicago Medical Center Clinical Laboratories

    Chicago, Illinois

  • Loyola University Medical Center

    Maywood, Illinois

  • University of Iowa

    Iowa City, Iowa

  • The University of Kansas Cancer Center Westwood

    Westwood, Kansas

  • University of Maryland Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Center Institute

    Detroit, Michigan

  • Washington University

    St Louis, Missouri

  • University of Nebraska

    Omaha, Nebraska

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Ichann School of Medicine at Mount Sinai

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Mayo Clinic

    Rochester, New York

  • Montefiore Medical Center

    The Bronx, New York

  • DUHS-Duke Blood Cancer Center

    Durham, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • James Cancer Hospital and Solove Research Institute

    Columbus, Ohio

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Prisma Health Cancer Institute

    Greenville, South Carolina

  • Tennessee Oncology, PLLC

    Nashville, Tennessee

  • Vanderbilt University

    Nashville, Tennessee

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.